Product Images Nucynta ER

This is a chart that indicates the percentage of patients who reported improvement in pain from baseline after a 15-week treatment period. There are two lines on the chart, one for Placebo and one for Nucynta ER. The percentage improvement in pain ranges from 0 to 100 on the y-axis and there are tick marks indicating intervals of 10. On the x-axis, there are tick marks indicating intervals of 10 for percent improvement in pain from baseline. There are also additional tick marks indicating percentiles within these intervals (e.g., 5, 15, 25, etc.).*

This is a chart showing the percentage of patients who improved their pain levels after using a medication, likely called Nucynta ER), compared to a placebo. The chart shows the percentage of improvement at various points between 0 and 100, and records the improvement after 12 weeks of use.*

This is a chart that displays the percentage of patients who improved in pain from the baseline after 12 weeks of a double-blind period. The chart compares the improvement between a placebo group and an NUCYNTA® ER group. The percentage of improvement is shown for different levels of pain relief, ranging from 10% to 100%.*

Nucynta ER (tapentadol) is an extended-release tablet used for moderate to severe pain relief. Each tablet contains 50 mg of tapentadol and should be swallowed whole, without chewing or crushing. Keep the medication out of reach of children and protected from moisture. Federal law prohibits transferring the drug to anyone other than the patient it was prescribed for. See the accompanying medication guide for each patient to follow the prescribed dosage. No other information is available.*

This is the packaging of Nucynta ER, an extended-release tablet containing tapentadol. Each tablet contains 150mg of tapentadol and should be swallowed whole without crushing or dissolving. Federal laws prohibit the transfer of this drug to anyone other than the patient for whom it was prescribed. The medication guide should also be given to each patient. It is recommended to keep the drug away from moisture and out of reach of children. The storage temperature should be between 15°C-30°C (50°F-36°F) or up to 25°C (77°F) as permitted by USP. No other useful information is available.*

Nucynta ER is a tablet containing 200mg of tapentadol, sold in a package of 60 tablets. It is an extended-release medication only available with a prescription. It is necessary to swallow the tablets whole, and they should not be chewed or dissolved. According to federal law, this drug cannot be transferred to anyone other than the patient for whom it was prescribed. A medication guide should be given to each patient along with the prescription. Dosage information is included in the package insert, and it should be kept out of the reach of children. A product code and a revision date are included at the bottom of the page.*

Nucynta ER (tapentadol) is an extended-release tablet used for managing pain. Each tablet contains 250mg tapentadol and should be swallowed whole, without chewing, crushing or dissolving. Transfer of the drug to any person other than the patient for whom it was prescribed is prohibited by federal law. The medication guide should be given to each patient. The drug should be stored at room temperature, protected from moisture and out of reach of children. For full prescribing information, refer to the package insert. No further information is available from this text.*